What Researchers Did
Researchers described the case of a 55-year-old man with chronic myeloid leukemia who developed pneumatosis intestinalis during nilotinib chemotherapy.
What They Found
A 55-year-old man with chronic myeloid leukemia developed pneumatosis intestinalis approximately 5 months after starting nilotinib. This condition resolved with five courses of hyperbaric oxygen therapy and other medications, while nilotinib was continued, leading to major and complete molecular responses for his leukemia at 6 and 18 months, respectively.
What This Means for Canadian Patients
Canadian patients receiving nilotinib for chronic myeloid leukemia should be aware of rare gastrointestinal complications like pneumatosis intestinalis. If such symptoms arise, prompt medical attention is crucial, as effective treatments exist that may allow continuation of their leukemia therapy.
Canadian Relevance
This study has no direct Canadian connection.
Study Limitations
As a single case report, the findings of this study cannot be generalized to a broader patient population.